Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Halima Abahssain

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
BMC Gastroenterology|October 14, 2016
Quality of life of early stage colorectal cancer patients in MoroccoHind Mrabti, Mounia Amziren, Ibrahim ElGhissassi, et al.
Tumori|October 20, 2020
Frequency and types of <i>EGFR</i> mutations in Moroccan patients with non-small cell lung cancerMohamed Lemine Sow, Hind El Yacoubi, Badreddine Moukafih, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Clinical & Experimental Metastasis|September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 datasetAlessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Clinical and Experimental Medicine|November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 studyMatteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Scientific Reports|March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumabLorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 studyFrancesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
BMC Gastroenterology|October 14, 2016
Quality of life of early stage colorectal cancer patients in MoroccoHind Mrabti, Mounia Amziren, Ibrahim ElGhissassi, et al.
Tumori|October 20, 2020
Frequency and types of <i>EGFR</i> mutations in Moroccan patients with non-small cell lung cancerMohamed Lemine Sow, Hind El Yacoubi, Badreddine Moukafih, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
Clinical & Experimental Metastasis|September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 datasetAlessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Clinical and Experimental Medicine|November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 studyMatteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Scientific Reports|March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumabLorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 studyFrancesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Pageof 4